WO2003042367A3 - Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail - Google Patents

Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail Download PDF

Info

Publication number
WO2003042367A3
WO2003042367A3 PCT/US2002/036431 US0236431W WO03042367A3 WO 2003042367 A3 WO2003042367 A3 WO 2003042367A3 US 0236431 W US0236431 W US 0236431W WO 03042367 A3 WO03042367 A3 WO 03042367A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
immunospecifically bind
relates
trail receptors
trail
Prior art date
Application number
PCT/US2002/036431
Other languages
English (en)
Other versions
WO2003042367A2 (fr
Inventor
Theodora Salcedo
Victor Roschke
Steven M Ruben
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Theodora Salcedo
Victor Roschke
Steven M Ruben
Craig A Rosen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Theodora Salcedo, Victor Roschke, Steven M Ruben, Craig A Rosen filed Critical Human Genome Sciences Inc
Priority to AU2002352676A priority Critical patent/AU2002352676A1/en
Publication of WO2003042367A2 publication Critical patent/WO2003042367A2/fr
Publication of WO2003042367A3 publication Critical patent/WO2003042367A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps et des molécules associées qui se lient spécifiquement au niveau immunitaire à des récepteurs TRAIL. On utilise ces anticorps, par exemple, dans la prévention et le traitement de cancers et d'autres troubles prolifératifs. Cette invention a également trait à des molécules d'acides nucléiques codant des anticorps du récepteur anti-TRAIL, à des vecteurs et à des cellules hôtes renfermant ces acides nucléiques, et à des méthodes d'élaboration correspondantes. Ladite invention a aussi pour objet des méthodes et des compositions de prévention, de détection, de diagnostic, de traitement ou d'amélioration d'une maladie ou d'un trouble, notamment le cancer et d'autres troubles hyperprolifératifs, lesdites méthodes consistant à administrer à un animal, de préférence à un être humain, une quantité efficace d'au moins un anticorps ou un fragment ou un variant associé ou une molécule correspondante qui se lie spécifiquement au niveau immunitaire à des récepteurs TRAIL.
PCT/US2002/036431 2001-11-14 2002-11-13 Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail WO2003042367A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002352676A AU2002352676A1 (en) 2001-11-14 2002-11-13 Antibodies that immunospecifically bind to trail receptors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33130901P 2001-11-14 2001-11-14
US60/331,309 2001-11-14
US37797302P 2002-05-07 2002-05-07
US60/377,973 2002-05-07
US40337602P 2002-08-15 2002-08-15
US60/403,376 2002-08-15

Publications (2)

Publication Number Publication Date
WO2003042367A2 WO2003042367A2 (fr) 2003-05-22
WO2003042367A3 true WO2003042367A3 (fr) 2004-01-29

Family

ID=27406783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036431 WO2003042367A2 (fr) 2001-11-14 2002-11-13 Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail

Country Status (2)

Country Link
AU (1) AU2002352676A1 (fr)
WO (1) WO2003042367A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094880A1 (fr) 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anticorps anti-trail-r
EP1409544B1 (fr) 2001-07-03 2009-06-17 Genentech, Inc. Anticorps humains du dr4 et utilisations
WO2005000894A2 (fr) 2003-06-25 2005-01-06 Crucell Holland B.V. Molecules de liaison pour traiter les malignites de cellules myeloides
CA2575755C (fr) 2004-08-06 2014-04-08 Genentech, Inc. Dosages et procedes mettant en oeuvre des biomarqueurs
RU2431676C2 (ru) 2004-08-06 2011-10-20 Дженентек, Инк. Анализы и способы с применением биомаркеров
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ES2380119T3 (es) 2005-08-16 2012-05-08 Genentech, Inc. Sensibilidad apoptótica a APO2L/TRAIL analizando la expresión de GalNac-T14 en células/tejidos

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFITH T.S. ET AL.: "Functional analysis of TRAIL receptors using monoclonal antibodies", J. IMMUNOL., vol. 162, 1999, pages 2597 - 2605, XP002944456 *
MARIANI S.M. ET AL.: "Interleukin 1beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells", J. CELL BIOL., vol. 137, no. 1, 7 April 1997 (1997-04-07), pages 221 - 229, XP002045027 *
MUHLENBECK F. ET AL.: "The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation", J. BIOL. CHEM., vol. 275, no. 41, 13 October 2000 (2000-10-13), pages 32208 - 32213, XP001062214 *

Also Published As

Publication number Publication date
WO2003042367A2 (fr) 2003-05-22
AU2002352676A1 (en) 2003-05-26

Similar Documents

Publication Publication Date Title
WO2003054216A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
WO2002097033A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2001001748A3 (fr) Composés se liant à her2
WO2002094192A3 (fr) Anticorps contre le facteur de necrose tumorale delta (april)
WO2003055979A3 (fr) Anticorps se liant à blys selon un mode immunospécifique
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
BR0306973A (pt) Anticorpos anti-igf-ir e respectivas aplicações
WO2004000997A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
WO2004013287A3 (fr) Anticorps diriges contre le recepteur c3a
WO2001059064A3 (fr) Acides nucleiques, proteines et anticorps
EP2348051A3 (fr) Anticorps anti-CD20 avec une augmentation de l'affinité au récepteur à Fc et de la fonction effectrice
WO2004100898A3 (fr) Utilisation therapeutique d'anticorps anti-cs1
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
WO2003089575A3 (fr) Anticorps se liant specifiquement au tl5
WO2005016236A3 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
WO2003085093A3 (fr) Anticorps se liant specifiquement a gmad
WO2003102136A3 (fr) Anticorps se fixant specifiquement a la neurokinine b
WO2004003144A3 (fr) Anticorps qui se lient specifiquement a reg iv
WO2003042367A3 (fr) Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail
WO2002079377A3 (fr) Anticorps a liaison immunospecifique avec les recepteurs 'trail'
WO2001060990A3 (fr) Nouvelles kinases de sphingosine
WO2004016753A3 (fr) Anticorps se fixant de facon immunospecifique a des recepteurs trail
WO2003092597A3 (fr) Anticorps a liaison specifique avec la chimiokine beta-4 (ck-b4)
WO2003086301A3 (fr) Anticorps se liant specifiquement a tr2
WO2005018536A3 (fr) Anticorps agonistes de liaison specifique au recepteur de peptide 1 assimile au glucagon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP